1. Home
  2. GLPG vs WD Comparison

GLPG vs WD Comparison

Compare GLPG & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$29.98

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Walker & Dunlop Inc

WD

Walker & Dunlop Inc

HOLD

Current Price

$44.38

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLPG
WD
Founded
1999
1937
Country
Belgium
United States
Employees
704
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
GLPG
WD
Price
$29.98
$44.38
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$36.50
$78.33
AVG Volume (30 Days)
150.8K
386.5K
Earning Date
04-22-2026
04-30-2026
Dividend Yield
N/A
6.25%
EPS Growth
N/A
N/A
EPS
N/A
1.64
Revenue
N/A
$1,234,306,000.00
Revenue This Year
N/A
$20.60
Revenue Next Year
N/A
$7.79
P/E Ratio
N/A
$26.51
Revenue Growth
N/A
8.99
52 Week Low
$22.59
$42.12
52 Week High
$37.78
$90.00

Technical Indicators

Market Signals
Indicator
GLPG
WD
Relative Strength Index (RSI) 40.25 36.15
Support Level $28.78 $42.12
Resistance Level $33.67 $66.25
Average True Range (ATR) 0.86 1.65
MACD -0.28 0.41
Stochastic Oscillator 30.85 30.62

Price Performance

Historical Comparison
GLPG
WD

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About WD Walker & Dunlop Inc

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

Share on Social Networks: